Alkermes (ALKS) is a mid-cap biopharmaceutical company focused on drug development for chronic central nervous system diseases, such as schizophrenia, major depressive disorder and multiple sclerosis. The company has two approved drugs, ARISTADA (aripiprazole lauroxil) for the treatment of schizophrenia in adults, and VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol dependence as well as for the prevention of relapse to opioid dependence, following opioid detoxification.
Alkermes also granted US licenses of technologies to these companies, from whom they receive royalties:
With AstraZeneca (AZN): BYDUREON (exenatide extended-release for injectable suspension)